Taken together, these studies strongly suggest that cancer cells harboring inactivated pRB may be selectively affected by targeted anti-glutamine strategies, including several glutaminase inhibitors that are currently in pre-clinical development (i.e. BPTES, c968, and CB-839). This evidence concerns the gene RB1 and cancer.